Using lymphatic OMT techniques to augment the response to the mRNA COVID vaccination

This study examined whether adding osteopathic manipulative treatment (OMT) with lymphatic pump techniques to standard mRNA COVID-19 vaccination could augment immune responses and reduce breakthrough illness. Conducted in the context of first-dose Pfizer-BioNTech (BNT162b2) vaccinations in 2021, the study enrolled 104 subjects randomized to receive either OMT at each vaccination or no OMT. Ninety-one participants completed the primary vaccination series and were analyzed for immunologic endpoints. Baseline serology separated participants into COVID-19-naïve (n=51) and COVID-19-pre-exposed (n=40) groups; the primary analysis focused on the naïve cohort due to data homogeneity. Primary endpoints measured time-resolved and cumulative anti-SARS-CoV-2 spike protein IgG titers, along with anti-nucleocapsid and neutralizing antibody measurements. Secondary endpoints included frequency, severity, and duration of breakthrough infection symptoms and medication use during breakthrough illness.

In COVID-19-naïve subjects, the OMT group demonstrated significantly increased anti-spike IgG titers at three weeks post-vaccination compared with controls (p = 0.038). Cumulative antibody responses, assessed at five and 13 weeks, were also significantly higher in the OMT-treated naïve cohort (p = 0.046 at five weeks; p = 0.009 at 13 weeks). An intention-to-treat analysis across all randomized subjects supported these findings, showing significant differences in titers between OMT and control groups at three weeks (p < 0.001) and in area-under-the-curve (AUC) titers at 13 weeks (p = 0.035). By contrast, participants who were pre-exposed to COVID-19 did not exhibit significant differences in antibody responses between OMT and control arms, suggesting the intervention’s measurable benefit was most apparent in seronegative individuals receiving primary immunization.

Clinical outcomes during breakthrough infections also favored the OMT group. Both arms experienced ten breakthrough infections, but OMT-treated participants reported fewer and less severe symptoms. Symptom duration in breakthrough cases was reduced from a mean of eight days in controls to 4.5 days in the OMT group (p = 0.013). Duration of medication use during breakthrough illness was shorter among OMT-treated subjects (1.5 days versus 5 days in controls; p = 0.014). These findings indicate that lymphatic-focused OMT may not only accelerate and amplify early vaccine-induced antibody production in naïve recipients but also mitigate clinical impact when breakthrough infections occur.

The trial situates its rationale within prior preclinical and small human pilot studies suggesting OMT can enhance immune function by improving lymphatic circulation through targeted myofascial and pump techniques. The authors conclude that OMT-treated subjects developed quicker and stronger vaccine-induced antibody titers and experienced significantly shorter, less severe breakthrough symptoms, supporting further investigation of OMT as an adjunct to vaccination protocols. The study underscores the potential value of nonpharmacologic, manual therapies to augment vaccine responses and reduce symptomatic burden, particularly in vaccine-naïve populations, while noting that benefits were not observed in pre-exposed individuals in this trial.